The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.
VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.
EAN 2024 | Predicting phenoconversion in RBD
Luca Baldelli, MD, PhD, University of Bologna, Bologna, Italy, discusses how phenoconversion to centralized α-synucleinopathy can be predicted in patients with REM sleep behavior disorder (RBD). Some RBD patients present with subtle symptoms and signs relating to motor impairment, autonomic impairment, or cognitive impairment that are characteristic of α-synucleinopathies. This indicates a higher risk of phenoconversion. Loss in dopaminergic neurons, identified through dopamine transporter (DaT) scans, and certain structural and metabolic changes, seen via MRI, can also indicate high risk. Accumulation of α-synuclein in skin and the cerebrospinal fluid is also a biomarker for risk of phenoconversion. No single biomarker has shown significant accuracy to define the trajectory of phenoconversion in isolation and thus, and combination of these markers is most promising. This interview took place at the European Academy of Neurology (EAN) Annual Meeting 2024 in Helsinki, Finland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
